Formulation and in Vitro Evaluation of Liquisolid Compact of Celecoxib

¹Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria

²Department of Pharmaceutics, University of Hertfordshire, Hatfield, United Kingdom

³Department of Pharmaceutics, University of Nigeria, Nsukka, Nigeria

⁴Human and Natural Science Center, ABC Federal University, Santo Andre, Sao Paulo, Brazil

⁵Department of Home Science and Management, University of Nigeria, Nsukka, Nigeria

⁶Department of Pharmacology, Federal University of Technology, Owerri, Nigeria

*Corresponding authors

Ezegbe Chekwube Andrew, Department of Pharmaceutical Technology and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, Enugu State, Nigeria & Federal University of ABC (UFABC), Santo Andre, Brazil, Phone: +2348038042802, E-mail: [email protected]

Amarachi Grace Ezegbe, Department of Home Science and Management, Faculty of Agriculture, University of Nigeria Nsukka, Enugu State, Nigeria, Phone: +2348061114433, E-mail: [email protected]

Received Date: June 06, 2024

Published Date: July 05, 2024

Citation: Andrew EC, et al. (2024). Formulation and in Vitro Evaluation of Liquisolid Compact of Celecoxib. Mathews J Pharma Sci. 8(2):31.

Copyrights: Andrew EC, et al. © (2024).

ABSTRACT

Introduction: The pharmaceutical liquisolid technique has emerged as a promising approach for addressing the challenges associated with poorly water-soluble drugs. The solubility and bioavailability of drugs play a pivotal role in determining their therapeutic efficacy. Aim: To formulate and evaluate celecoxib tablets using the liquisolid technique, in order to enhance its dissolution rate and bioavailability. Method: Celecoxib tablets were prepared using the liquisolid technique by incorporating a non-volatile liquid medication carrier and a suitable coating material. Various formulations were developed by altering the ratios of drug, carrier, and coating materials. The prepared tablets were characterized for their physical properties, drug content uniformity, in vitro dissolution behavior, compatibility using Fourier-transform infrared (FTIR) spectroscopy, morphology using Scanning electron microscopy (SEM) and enthalpy changes using Differential scanning calorimetry (DSC). Results: The solubility profile showed that the maximum rate of dissolution was recorded in PEG-400 (11.03 ± 0.01) when compared to other non-volatile solvents. The angle of slide, indicated that the excipients used were within the acceptable limit of 33^o. The FTIR spectroscopy showed compatibility of the drug and excipients. The results of the SEM showed that spherically-shaped vesicles were formed. DSC showed the crystallinity nature of the excipients and the amorphous nature of the optimized formulation. Evaluation of the pre-compression parameters indicated that the drug content was highest in batch F-11 hence its optimization (96.1 ± 0.90 %). The post compression evaluation indicated that the official tests were within the acceptable range for disintegration time (2.25 ± 0.35 mins). The results of the in vitro release studies of the optimized formulation, conventional tablet and reference commercial tablet showed that the amount of drug released increased steadily with time over the 1-hour period. Conclusion: Our findings underscored its viability as a strategy to enhance the therapeutic efficacy of poorly water-soluble drugs. The in-vitro release showed that the liquisolid tablets performed better in terms of release (p < 0.05), when compared with the conventional formulation.

Keywords: Liquisolid, Celecoxib, Carrier, Coating material, Dissolution.